liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
University of Liege, Belgium .
Hospital Saint Antoine / Pierre-and-Marie-Curie University, Paris, France.
CHU Marseille, France .
Hospital Clinico Universitario, Salamanca, Spain.
Show others and affiliations
2014 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 49, no 3, 389-396 p.Article in journal (Refereed) Published
Abstract [en]

The impact of in vivo T-cell depletion on transplantation outcomes in patients transplanted with reduced-intensity conditioning (RIC) remains controversial. This study assessed the outcome of 1250 adult patients with de novo AML in first CR (CR1) given PBSC from HLA-identical siblings after chemotherapy-based RIC. A total of 554 patients did not receive any form of in vivo T-cell depletion (control group), whereas antithymocyte globulin (ATG) and alemtuzumab were given in 444 and 252 patients, respectively. The incidences of grade II-IV acute GVHD were 21.4, 17.6 and 10.2% in control, ATG and alemtuzumab patients, respectively (P less than 0.001). In multivariate analysis, the use of ATG and the use of alemtuzumab were each associated with a lower risk of chronic GVHD (P less than 0.001 each), but a similar risk of relapse, and of nonrelapse mortality, and similar leukemia-free survival and OS. Further, among patients given BU-based RIC, the use of less than 6 mg/kg ATG did not increase the risk of relapse (hazard ratio, HR=1.1), whereas there was a suggestion for higher relapse risk in patients given greater than= 6 mg/kg ATG (HR=1.4, P=0.08). In summary, these data suggest that a certain amount of in vivo T-Cell depletion can be safely used in the conditioning of AML patients in CR1 given PBSC after chemotherapy-based RIC.

Place, publisher, year, edition, pages
Nature Publishing Group, 2014. Vol. 49, no 3, 389-396 p.
Keyword [en]
reduced-intensity conditioning; AML; GVHD; ATG; alemtuzumab
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-106025DOI: 10.1038/bmt.2013.204ISI: 000332638100012PubMedID: 24419525OAI: diva2:712936
Available from: 2014-04-17 Created: 2014-04-17 Last updated: 2014-04-25Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Haematology
In the same journal
Bone Marrow Transplantation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 72 hits
ReferencesLink to record
Permanent link

Direct link